Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Monte Rosa Therapeutics and Cardiff Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
Monte Rosa Therapeutics currently has a consensus target price of $28.50, indicating a potential upside of 134.95%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 447.45%. Given Cardiff Oncology’s higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Monte Rosa Therapeutics.
Volatility & Risk
Insider & Institutional Ownership
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Monte Rosa Therapeutics and Cardiff Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $28.73 million | 36.02 | -$38.63 million | ($1.76) | -6.89 |
| Cardiff Oncology | $508,000.00 | 209.80 | -$45.85 million | ($0.60) | -2.28 |
Monte Rosa Therapeutics has higher revenue and earnings than Cardiff Oncology. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Monte Rosa Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
Summary
Monte Rosa Therapeutics beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
